Member Info for nforbes01

It would be good if they gave the shareholders a reason not to hate this stock at some point, 232 days since any update from the company... and counting.

There is no doubt they have enough money to spend on a new hire, from shareholders. After all it is an operational business.

A lack of route to profitability is the issue.

OSD, where do you see this?

"It is also interesting that independent analysts are now calling 1p target here within the next 3 months."

Ignore the AI slop that has been posted.

It’s insane there has been no news since October. You would thing they have done something with the circa 5 mil since then to report?

No material progress reported since the CFS test breakthrough. At this point this looks like it could be a potential huge winner for this company, 100% unique product. BUT zero information has been given since October 2025. No trials update. No patent update.

The prostate cancer test space seems to crowded for this expensive test to take priority over alternatives on the market (in the UK anyway). OBD provide the best test on the market but it looks like the UK only wants 'acceptable' and not the best. It needs to gain major traction in the US, quickly!

We are approaching 4 months without a news… no CFS trials progress or timeline, no Google cloud monetisation, no expansion of prostate cancer testing.

What is going on at Oxford Biodynamics?

It is caught in a vicious cycle, if the share price represented the potential of the company (e.g. 2-3p), the shareholders would not be diluted by nearly as much when funding, but now it's on it seems OBD are on their final chances to pull something off.

Yes, I'd roughly estimate (from their most recent numbers) monthly revenue is £120k to £140k at roughly 200 tests. Their target is 500 this year.

It would be good to see a substantial increase.

It's incredibly unlikely these Pfizer rumours are true. It's one or two people trying to pump the price, repeating statements from the RNS last year.

With a monthly burn rate of around 1m they should have at least 5m in the bank.

He is posting on as many BBs as possible to pump the price for a quick pump and dump

Https://www.urologytimes.com/view/episwitch-prostate-screening-blood-test-launches-on-us-market

First sentence: “The EpiSwitch Prostate Screening (PSE) blood test has been clinically validated…”

Second sentence: “The blood-based test was validated as a laboratory-developed test in a centralized high-complexity Clinical Laboratory Improvement Amendments-certified laboratory in Frederick, Maryland.”

In the announcement by Oxford BioDynamics PLC (“the Company”), the current and target monthly test volumes for their “EpiSwitch® PSE” prostate screening test are stated as follows:

Current monthly order level: 215 tests in September 2025. (£170k/month on avg £800 per test)

Target monthly volume: 500 tests/month within 12 months. (£400k/month on avg £800 per test)

1015 these shares are being bought via the funding share issue

The price won't go any higher until the shares have been released following the 7th November, selling shares at 0.33p per share is a free 10% arbitrage for intuitions with access to the share issue.

4 mil yes as the only reasonable vote, and buying more. I'd very much like to see directors do the same to show some faith in what's going on behind the scenes.

If you are right halfpenny we will see some director sells being reported. Pretty much all buys in the last year.

Slapper, your posts are hilarious 🤣 , who hurt you?

I think America is the companies best hopes, under an healthcare insurer deal. They already have a US HQ and exempt from tariffs.

For prostate detection, the NHS have already chosen to trial a different test (Stockholm3 I read on here)

OBD’s financial year ends on 30th September. Last year they gave an end of financial year update on the 14th October.

AJ Bell is not offering any buy quotes, only sell